NMN / NR (NAD+ boosters)
Last reviewed 25 August 2026 · Evidence-graded review — see Methodology
Nicotinamide mononucleotide and nicotinamide riboside raise NAD+, a molecule cells use for energy and repair that declines with age. Mice find this exciting. Humans so far show small shifts in metabolic markers, no meaningful clinical benefits, and unknown long-term safety. This is a legitimate research area being sold as a finished product.
A 2024 systematic review of randomised trials found NMN produced modest improvements in insulin sensitivity and lipid measures in some small studies, with heterogeneous designs, short durations and no hard endpoints anywhere. The mouse literature is genuinely interesting; age reversal in mice does not transfer at purchase. Multi-year outcome trials in humans have not been run.
Doing it: There is no evidence-supported dose, because there is no evidence-supported outcome. If you take it anyway, treat it as a self-funded experiment you have opted into, watch for side effects, and do not let it crowd out sleep, training or diet.
Who it suits: Curious early adopters comfortable burning money on uncertainty. Not recommended for anyone else yet.
Sources
Next in supplements: Resveratrol →
Prefer to start with what a blood test can tell you? All 48 diagnostic tests, ranked →